PerkinElmer, Centre for Genomic Regulation partner on diabetes gene therapy

By The Science Advisory Board staff writers

February 17, 2022 -- PerkinElmer's Sirion Biotech and the Centre for Genomic Regulation (CRG) entered into an agreement to jointly develop new generation adeno-associated virus (AAV) vectors for type 1 and type 2 diabetes gene therapy.

The collaboration combines Sirion's AAV technology platform and expertise in viral vector development and production with CRG's knowledge of genetic regulatory mechanisms. The end goal of the collaboration is to develop AAV vectors that target specific pancreatic cell types and contain payloads that express therapeutic genes under the control of cell-specific regulatory elements. The approach aims to increase the precision, safety, and efficacy of future AAV-based gene therapies for diabetes.

Financial details of the agreement were not disclosed.

CRG is a biomedical research center based in Barcelona, Spain, which has launched five spinoff companies since 2008. It is home to more than 400 interdisciplinary scientists.

PerkinElmer is a global provider of end-to-end solutions that help scientists, researchers, and clinicians better diagnose diseases and discover new and more personalized drugs.

PerkinElmer highlights new workflows at SLAS 2022
BOSTON - Following a series of acquisitions of Horizon Discovery, BioLegend, Nexcelom Bioscience, and Omni International in 2021, PerkinElmer showcased...
Carterra, PerkinElmer sign distribution agreement for antibody solutions
Carterra has signed an exclusive Asia-Pacific and Oceania region distribution agreement with PerkinElmer. According to the agreement, PerkinElmer will...
PerkinElmer launches remote lab management service
PerkinElmer has launched a new cloud-based remote lab management tool.
PerkinElmer unveils Signals Research Suite
PerkinElmer has introduced Signals Research Suite, a cloud-based informatics platform geared toward pharmaceutical and industrial customers.
PerkinElmer acquires BioLegend for $5.25B
PerkinElmer announced it has completed its $5.25 billion acquisition of life science antibody and reagent company BioLegend, a deal first announced in...

Copyright © 2022

Glasgow International Health Festival
January 25-26, 2023
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter